SCHEMBL25307251

SCHEMBL25307251

C[C@@H](N)c1ncc(C(F)(F)F)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.39
KMT2A Q03164 2/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PDE2A O00408 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TACR1 P25103 1/20 0.34
PLAU P00749 1/20 0.33
AGBL2 Q5U5Z8 1/20 0.33
NOS3 P29474 1/20 0.32
NOS2 P35228 1/20 0.32
OGA O60502 2/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22631514 1.00 POLB (0.39) POLBKMT2AHTR2AHTR2CHTR2B
SCHEMBL29628885 0.83 POLB (0.40) POLBKMT2AHTR2AHTR2CHTR2B
SCHEMBL15044981 0.82 POLB (0.44) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL16088943 0.81 KIF11 (0.46) POLBALDH1A1KDM4ECYP1A2
SCHEMBL18432398 0.78 NPSR1 (0.35) POLBKMT2AHTR2AHTR2CHTR2B
SCHEMBL15166038 0.78 NPSR1 (0.35) POLBKMT2AHTR2AHTR2CHTR2B
SCHEMBL15166035 0.78 NPSR1 (0.35) POLBKMT2AHTR2AHTR2CHTR2B
SCHEMBL14831262 0.78 MAPK1 (0.51) KMT2ASMN1; SMN2MAPK1NPSR1
SCHEMBL16088942 0.75 IDH1 (0.41) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL28542354 0.75 NPSR1 (0.33) POLBKMT2AHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223751-A1 BENZAMIDE COMPOUND AND USE THEREOF Humanwell Healthcare (Group) Co., Ltd. (CN) 2023-08-09 EP disclosed
EP-4223751-A1 BENZAMIDE COMPOUND AND USE THEREOF Humanwell Healthcare (Group) Co., Ltd. (CN) 2023-08-09 EP disclosed
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) 2023-07-20 US disclosed
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) 2023-07-20 US disclosed
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) 2023-07-20 US disclosed
CN-114315818-A Benzamide compound and application thereof 武汉人福创新药物研发中心有限公司 2022-04-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227445-A1 BENZAMIDE COMPOUND AND USE THEREOF P2RX3, P2RX4, P2RX7 POLB 4500/4885KMT2A 2860/4885HTR2A 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.